Detalhe da pesquisa
1.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Blood
; 143(17): 1713-1725, 2024 Apr 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38194692
2.
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
N Engl J Med
; 386(7): 629-639, 2022 02 17.
Artigo
Inglês
| MEDLINE | ID: mdl-34904798
3.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 380(1): 45-56, 2019 01 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30501490
4.
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Blood
; 130(21): 2317-2325, 2017 11 23.
Artigo
Inglês
| MEDLINE | ID: mdl-28935694
5.
Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy.
Hum Vaccin Immunother
; 19(1): 2210046, 2023 12 31.
Artigo
Inglês
| MEDLINE | ID: mdl-37185251
6.
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Nat Med
; 28(2): 325-332, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34921238
7.
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy.
Blood Adv
; 5(2): 593-601, 2021 01 26.
Artigo
Inglês
| MEDLINE | ID: mdl-33496754
8.
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Blood Adv
; 5(23): 4980-4991, 2021 12 14.
Artigo
Inglês
| MEDLINE | ID: mdl-34432863
9.
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
Blood Adv
; 4(3): 560-572, 2020 02 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32045475
10.
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.
Blood Adv
; 3(14): 2230-2236, 2019 07 23.
Artigo
Inglês
| MEDLINE | ID: mdl-31332046
11.
Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells.
CPT Pharmacometrics Syst Pharmacol
; 8(5): 285-295, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30848084
12.
Relating Observed Psychoactive Effects to the Plasma Concentrations of Delta-9-Tetrahydrocannabinol and Its Active Metabolite: An Effect-Compartment Modeling Approach.
J Pharm Sci
; 107(2): 745-755, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28942005
13.
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
Clin Cancer Res
; 24(24): 6175-6184, 2018 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30190371
14.
A Physiologically Based Pharmacokinetic Model to Describe Artemether Pharmacokinetics in Adult and Pediatric Patients.
J Pharm Sci
; 105(10): 3205-3213, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27506269